Original Article
Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects

https://doi.org/10.1016/j.jcf.2010.08.019Get rights and content
Under an Elsevier user license
open archive

Abstract

Background

Reducing nebulisation times for tobramycin solution for inhalation in cystic fibrosis (CF) may improve compliance.

Methods

In this single-dose, open-label, two-way crossover study, 13 subjects (7 CF, 6 healthy) were randomised to receive tobramycin via eFlow rapid or LC Plus jet nebuliser. Drug deposition in the lung using gamma scintigraphic imaging, nebulisation times, pharmacokinetics, and safety were evaluated.

Results

In CF patients, whole-lung deposition was 40% less with the eFlow rapid compared with LC Plus nebulisers was (8.9 ± 0.8%, and 15.1 ± 6.0%, p > 0.05). Nebulisation time was shorter with eFlow rapid compared to LC Plus (7.0 min versus 20.0 min, p < 0.05). Lung deposition in healthy subjects was comparable between both devices.

Conclusions

eFlow rapid reduces the nebulisation time of tobramycin and can potentially improved compliance in patients with CF.

Keywords

Cystic fibrosis
Nebuliser
Tobramycin
Aerosol
Pharmacokinetics
Pharmacoscintigraphy

Cited by (0)